ARNA:NSD-Arena Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 55.50

Change

-1.44 (-2.53)%

Market Cap

USD 3.50B

Volume

0.83M

Avg Analyst Target

USD 99.50 (+79.28%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with Second Genome, Inc.; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; Eisai Inc.; and Aristea Therapeutics, Inc. for the development of RIST4721 for treatment of serious immune-mediated inflammatory diseases. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. Address: 136 Heber Avenue, Park City, UT, United States, 84060

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

USD22.91B 30.56 12.22

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

-0.92 (-2.00%)

USD0.23B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.41 (-2.92%)

USD1.61B
MJX ETFMG Alternative Harvest.. 0.00 % 0.00 %

N/A

N/A
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

-0.23 (-2.00%)

N/A
FLWG:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-8.38 (-1.76%)

N/A
FLWR:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-0.08 (-1.19%)

N/A
BLUM:XETRA Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

-0.11 (-1.94%)

USD0.04B
CBSX:XETRA Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

-0.23 (-2.31%)

USD0.04B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

N/A
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.00 %

N/A

N/A
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.76% 42% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.76% 42% F 18% F
Trailing 12 Months  
Capital Gain -33.46% 29% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.46% 29% F 10% F
Trailing 5 Years  
Capital Gain 265.13% 82% B- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 265.13% 82% B- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 51.70% 76% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.70% 76% C 85% B
Risk Return Profile  
Volatility (Standard Deviation) 62.86% 49% F 28% F
Risk Adjusted Return 82.24% 96% A 88% B+
Market Capitalization 3.50B 90% A- 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 51% F 82% B-
Price/Book Ratio 3.80 47% F 37% F
Price / Cash Flow Ratio -9.91 58% F 72% C-
EV/EBITDA 3.52 41% F 86% B
Management Effectiveness  
Return on Equity -43.74% 64% D 30% F
Return on Invested Capital -38.11% 61% D- 21% F
Return on Assets -26.32% 48% F 14% F
Debt to Equity Ratio 3.81% 65% D 81% B-
Technical Ratios  
Short Ratio 4.95 47% F 30% F
Short Percent 4.52% 52% F 37% F
Beta 0.44 86% B 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector